ECSP10010160A - Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) - Google Patents
Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep)Info
- Publication number
- ECSP10010160A ECSP10010160A EC2010010160A ECSP10010160A ECSP10010160A EC SP10010160 A ECSP10010160 A EC SP10010160A EC 2010010160 A EC2010010160 A EC 2010010160A EC SP10010160 A ECSP10010160 A EC SP10010160A EC SP10010160 A ECSP10010160 A EC SP10010160A
- Authority
- EC
- Ecuador
- Prior art keywords
- arb
- nep
- antagonist
- super
- inhibitor
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003729 Neprilysin Human genes 0.000 title 2
- 108090000028 Neprilysin Proteins 0.000 title 2
- 229940125364 angiotensin receptor blocker Drugs 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000006186 oral dosage form Substances 0.000 abstract 2
- 239000007787 solid Substances 0.000 abstract 2
- -1 (1S, 3R) -1-biphenyl-4-yl-methyl-3-ethoxy-carbonyl-1-butyl-carbamoyl Chemical group 0.000 abstract 1
- 238000005056 compaction Methods 0.000 abstract 1
- 238000007907 direct compression Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000009490 roller compaction Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Las formas de dosificación oral sólidas, en especial tabletas, de una composición farmacéutica que comprende un complejo supramolecular, se pueden formar a partir de un proceso de compresión directa o de un proceso de compactación, tal como compactación con rodillos. Estas formas de dosificación oral sólida proporcionan un perfil de liberación inmediata que permite tener una rápida liberación del agente terapéutico. Un complejo supramolecular particularmente útil es el propionato-(S)-3'-metil-2'-(pentanoil-{2"-(tetrazol-5-ilato)-bifenil-4'-il-metil}-amino)-butirato]-hemipentahidrato de [3-((1S,3R)-1-bifenil-4-il-metil-3-etoxi-carbonil-1-butil-carbamoílo) de trisodio
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98566807P | 2007-11-06 | 2007-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010160A true ECSP10010160A (es) | 2010-06-29 |
Family
ID=40451030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010160A ECSP10010160A (es) | 2007-11-06 | 2010-05-06 | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US20100267786A1 (es) |
| EP (4) | EP3067043B1 (es) |
| JP (2) | JP5653218B2 (es) |
| KR (2) | KR101700062B1 (es) |
| CN (2) | CN103251587A (es) |
| AR (1) | AR069184A1 (es) |
| AU (1) | AU2008324878B2 (es) |
| BR (1) | BRPI0823505A2 (es) |
| CA (1) | CA2703598C (es) |
| CL (1) | CL2008003298A1 (es) |
| CY (2) | CY1116280T1 (es) |
| DK (3) | DK2295035T3 (es) |
| EC (1) | ECSP10010160A (es) |
| ES (3) | ES2587336T3 (es) |
| FI (1) | FI3067043T3 (es) |
| GT (1) | GT201000131A (es) |
| HR (3) | HRP20230178T3 (es) |
| HU (2) | HUE061321T2 (es) |
| IL (3) | IL262990B2 (es) |
| JO (1) | JOP20080499B1 (es) |
| MA (1) | MA31797B1 (es) |
| MX (1) | MX2010004930A (es) |
| MY (1) | MY153730A (es) |
| NZ (1) | NZ584686A (es) |
| PE (2) | PE20091390A1 (es) |
| PL (3) | PL2217205T3 (es) |
| PT (3) | PT3067043T (es) |
| RU (1) | RU2493844C3 (es) |
| SG (1) | SG185951A1 (es) |
| SI (3) | SI2295035T1 (es) |
| TN (1) | TN2010000200A1 (es) |
| TW (1) | TWI484982B (es) |
| WO (1) | WO2009061713A1 (es) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ584686A (en) | 2007-11-06 | 2013-03-28 | Novartis Ag | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate |
| SG176009A1 (en) | 2009-05-28 | 2011-12-29 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| JP5466759B2 (ja) | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| AU2011293648B2 (en) | 2010-08-24 | 2015-02-12 | Novartis Ag | Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| AU2013304949C1 (en) * | 2012-08-24 | 2020-12-24 | Novartis Ag | NEP inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| TR201808541T4 (tr) | 2013-02-14 | 2018-07-23 | Novartis Ag | Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri. |
| JP6301371B2 (ja) | 2013-02-14 | 2018-04-11 | ノバルティス アーゲー | インビボ効力が改善されたｎｅｐ阻害剤としての置換ビスフェニルブタン酸誘導体 |
| ES2968541T3 (es) | 2013-08-26 | 2024-05-10 | Novartis Ag | Tratamiento de enfermedades cardiovasculares |
| EP3038653A1 (en) | 2013-08-26 | 2016-07-06 | Novartis AG | New use |
| WO2015154673A1 (en) * | 2014-04-10 | 2015-10-15 | Zhaoyin Wang | Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases |
| CN105461647B (zh) * | 2014-09-28 | 2018-06-29 | 四川海思科制药有限公司 | 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途 |
| CN110938042B (zh) | 2014-12-08 | 2022-12-13 | 苏州晶云药物科技股份有限公司 | 一种包含缬沙坦和ahu377的三钠盐超分子复合物的新晶型及其制备方法 |
| CN104473938B (zh) * | 2014-12-30 | 2017-06-09 | 北京瑞都医药科技有限公司 | 一种治疗慢性心衰药物及其制备方法 |
| CN104826115A (zh) * | 2015-04-19 | 2015-08-12 | 浙江巨泰药业有限公司 | 一种抗心衰药物组合物及其制备方法 |
| EP4570314A3 (en) | 2015-05-11 | 2025-09-10 | Novartis AG | Sacubitril-valsartan dosage regimen for treating chronic systolic heart failure |
| WO2016193883A1 (en) | 2015-05-29 | 2016-12-08 | Novartis Ag | Sacubitril and valsartan for treating metabolic disease |
| CN106309388A (zh) * | 2015-06-30 | 2017-01-11 | 深圳信立泰药业股份有限公司 | 一种用于心衰治疗的药物组合物及其制备方法 |
| WO2017006254A1 (en) | 2015-07-08 | 2017-01-12 | Novartis Ag | Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist |
| CN106176723A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种固体药物组合物及其制备方法 |
| CN106176724A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种稳定的固体药物组合物及其制备方法 |
| CN106176725A (zh) * | 2015-07-11 | 2016-12-07 | 凌莉 | 一种提高稳定性的药物组合物及其制备方法和用途 |
| CN106074421A (zh) * | 2015-07-11 | 2016-11-09 | 凌莉 | 一种提高稳定性的药物组合物 |
| CN105997993B (zh) * | 2015-07-11 | 2018-03-30 | 麦丽芳 | 一种用于心血管疾病治疗的固体口服型制剂及其制备方法 |
| CN105997994A (zh) * | 2015-07-11 | 2016-10-12 | 凌莉 | 一种固体口服型制剂及其制备方法 |
| WO2017012600A1 (en) | 2015-07-20 | 2017-01-26 | Zentiva, K.S. | A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof |
| CN106397249A (zh) * | 2015-08-03 | 2017-02-15 | 深圳信立泰药业股份有限公司 | 一种高稳定性lcz696结晶粉末及其制备方法 |
| WO2017037577A1 (en) | 2015-08-28 | 2017-03-09 | Novartis Ag | New use |
| WO2017037596A1 (en) * | 2015-08-28 | 2017-03-09 | Dr. Reddy's Laboratories Limited | Amorphous solid dispersion of lcz-696 |
| US20180303799A1 (en) * | 2015-10-16 | 2018-10-25 | Shenzhen Salubris Pharmaceuticals Co., Ltd | An Oral Preparation for the Treatment of Cardiovascular Disease and Its Preparation Method |
| CN105669581B (zh) * | 2015-11-09 | 2017-03-22 | 成都苑东生物制药股份有限公司 | 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物 |
| WO2017085573A1 (en) * | 2015-11-20 | 2017-05-26 | Lupin Limited | Amorphous sacubitril-valsartan complex and process for preparation thereof |
| CN105330609B (zh) * | 2015-12-07 | 2017-12-22 | 南京正大天晴制药有限公司 | 一种制备lcz696的方法 |
| CN105935358B (zh) * | 2015-12-18 | 2019-06-07 | 重庆两江药物研发中心有限公司 | 一种沙库比曲缬沙坦缓释剂及其制备方法 |
| CN105929031B (zh) * | 2015-12-18 | 2018-08-21 | 重庆两江药物研发中心有限公司 | 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法 |
| CN106905253B (zh) * | 2015-12-23 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 一种超分子复合物的结晶 |
| US10722471B2 (en) | 2016-02-03 | 2020-07-28 | Novartis Ag | Galenic formulations of organic compounds |
| JP7156945B2 (ja) * | 2016-02-03 | 2022-10-19 | ノバルティス アーゲー | 有機化合物のガレヌス製剤 |
| CN105748420B (zh) * | 2016-03-04 | 2018-11-06 | 山东省药学科学院 | 一种治疗心力衰竭的lcz696缓释骨架片的制备方法 |
| CN105902506A (zh) * | 2016-06-12 | 2016-08-31 | 佛山市腾瑞医药科技有限公司 | 一种沙卡布曲缬沙坦制剂及其应用 |
| WO2018069937A1 (en) | 2016-10-13 | 2018-04-19 | Mylan Laboratories Limited | Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof |
| EP3600255B1 (en) * | 2017-03-31 | 2021-07-07 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Stable hot-melt extrudate containing valsartan and sacubitril |
| WO2018178295A1 (en) | 2017-03-31 | 2018-10-04 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Stable hot-melt extrudate containing valsartan and sacubitril |
| WO2018211479A1 (en) * | 2017-05-19 | 2018-11-22 | Lupin Limited | Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof |
| WO2019008485A1 (en) * | 2017-07-06 | 2019-01-10 | Mankind Pharma Ltd | FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL |
| WO2019020706A1 (en) | 2017-07-28 | 2019-01-31 | Synthon B.V. | PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN |
| US20200276129A1 (en) | 2017-10-13 | 2020-09-03 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Tablet containing valsartan and sacubitril |
| WO2019180735A1 (en) * | 2018-03-19 | 2019-09-26 | Natco Pharma Limited | Stable pharmaceutical compositions comprising sacubitril-valsartan complex |
| US11877576B2 (en) | 2018-06-22 | 2024-01-23 | Ideaz, Llc | Diphenyl tablets and methods of preparing the same |
| WO2020039386A1 (en) | 2018-08-23 | 2020-02-27 | Novartis Ag | New pharmaceutical use for the treatment of heart failure |
| WO2020039394A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | New drug combinations |
| EP3766484B1 (en) | 2019-07-19 | 2021-08-25 | Zentiva, K.S. | Solid pharmaceutical dosage form comprising valsartan and sacubitril |
| KR102545274B1 (ko) | 2020-02-26 | 2023-06-20 | 에리슨제약(주) | 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법 |
| KR20210120560A (ko) | 2020-03-27 | 2021-10-07 | 주식회사 유영제약 | 고함량의 주성분을 포함하는 정제 및 그 제조방법 |
| KR20210138510A (ko) | 2020-05-12 | 2021-11-19 | 에리슨제약(주) | 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제 |
| KR20220091767A (ko) | 2020-12-24 | 2022-07-01 | 주식회사 보령 | 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물 |
| KR102486815B1 (ko) | 2021-01-20 | 2023-01-10 | 주식회사 대웅제약 | Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US608220A (en) | 1898-08-02 | Mechanical movement | ||
| US607893A (en) | 1898-07-26 | Automatic switch-operating machine | ||
| US607355A (en) | 1898-07-12 | Carrier for bicycles | ||
| US735093A (en) | 1903-01-31 | 1903-08-04 | Oscar Greenwald | Elevator-cable guard. |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| US6558699B2 (en) * | 1997-11-17 | 2003-05-06 | Smithkline Beecham Corporation | High drug load immediate and modified release oral dosage formulations and processes for their manufacture |
| NZ504565A (en) * | 1997-11-17 | 2002-11-26 | Smithkline Beecham Corp | High drug load immediate and modified release oral dosage formulations of eprosartan used to block angiotensin II (AII) receptors in the treatment of hypertension, congestive heart failure and renal failure |
| AU750122C (en) * | 1998-06-17 | 2003-02-27 | Bristol-Myers Squibb Company | Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination |
| CN1304000C (zh) * | 1998-12-23 | 2007-03-14 | 诺瓦提斯公司 | 缬沙坦在制备用于治疗肺癌的药物中的用途 |
| AR032758A1 (es) | 2000-07-19 | 2003-11-26 | Novartis Ag | Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos |
| US7468390B2 (en) * | 2002-01-17 | 2008-12-23 | Novartis Ag | Methods of treatment and pharmaceutical composition |
| NZ533968A (en) | 2002-01-17 | 2006-10-27 | Novartis Ag | Pharmaceutical compositions comprising valsartan and nep inhibitors |
| JP3751287B2 (ja) * | 2002-03-27 | 2006-03-01 | バイエル薬品株式会社 | 小型化されたニフェジピン有核錠剤 |
| WO2003089417A1 (en) | 2002-04-15 | 2003-10-30 | Dr. Reddy's Laboratories Limited | Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan) |
| GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
| ES2238022T3 (es) | 2003-03-17 | 2008-11-01 | Teva Pharmaceutical Industries Ltd. | Poliformos de valsartan. |
| JP2009513543A (ja) * | 2003-07-16 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | クロルタリドンの組み合わせ |
| GB0402262D0 (en) * | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
| GT200600371A (es) | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
| WO2007049292A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Pharmaceutical formulation of losartan |
| US20080227836A1 (en) | 2005-10-31 | 2008-09-18 | Lupin Ltd | Stable Solid Oral Dosage Forms of Valsartan |
| EP2260755B1 (en) | 2005-11-07 | 2013-12-25 | Stryker Corporation | Patient handling device including normal condition lamp |
| KR20080066776A (ko) | 2005-11-08 | 2008-07-16 | 노파르티스 아게 | 안지오텐신 ⅱ 수용체 봉쇄제, 칼슘 채널 봉쇄제 및 다른활성 약제의 조합물 |
| AR057882A1 (es) * | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| EP1897537A1 (en) * | 2006-09-04 | 2008-03-12 | Novartis AG | Composition comprising an angiotensin II receptor antagonist |
| NZ584686A (en) | 2007-11-06 | 2013-03-28 | Novartis Ag | Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate |
-
2008
- 2008-11-04 NZ NZ584686A patent/NZ584686A/xx unknown
- 2008-11-04 FI FIEP16157767.1T patent/FI3067043T3/fi active
- 2008-11-04 HR HRP20230178TT patent/HRP20230178T3/hr unknown
- 2008-11-04 HR HRP20150459TT patent/HRP20150459T1/hr unknown
- 2008-11-04 ES ES10173506.6T patent/ES2587336T3/es active Active
- 2008-11-04 PT PT161577671T patent/PT3067043T/pt unknown
- 2008-11-04 DK DK10173506.6T patent/DK2295035T3/en active
- 2008-11-04 DK DK16157767.1T patent/DK3067043T3/da active
- 2008-11-04 EP EP16157767.1A patent/EP3067043B1/en active Active
- 2008-11-04 MY MYPI2010001722A patent/MY153730A/en unknown
- 2008-11-04 PL PL08848154T patent/PL2217205T3/pl unknown
- 2008-11-04 JO JOP/2008/0499A patent/JOP20080499B1/ar active
- 2008-11-04 IL IL262990A patent/IL262990B2/en unknown
- 2008-11-04 MX MX2010004930A patent/MX2010004930A/es active IP Right Grant
- 2008-11-04 AU AU2008324878A patent/AU2008324878B2/en active Active
- 2008-11-04 PE PE2008001886A patent/PE20091390A1/es not_active Application Discontinuation
- 2008-11-04 SI SI200831654A patent/SI2295035T1/sl unknown
- 2008-11-04 AR ARP080104826A patent/AR069184A1/es not_active Application Discontinuation
- 2008-11-04 BR BRPI0823505-8A patent/BRPI0823505A2/pt not_active Application Discontinuation
- 2008-11-04 EP EP10173506.6A patent/EP2295035B1/en not_active Revoked
- 2008-11-04 PL PL16157767.1T patent/PL3067043T3/pl unknown
- 2008-11-04 CA CA2703598A patent/CA2703598C/en active Active
- 2008-11-04 HU HUE16157767A patent/HUE061321T2/hu unknown
- 2008-11-04 ES ES16157767T patent/ES2939163T3/es active Active
- 2008-11-04 RU RU2010123027A patent/RU2493844C3/ru active
- 2008-11-04 DK DK08848154.4T patent/DK2217205T3/en active
- 2008-11-04 PT PT101735066T patent/PT2295035T/pt unknown
- 2008-11-04 CN CN2013101540642A patent/CN103251587A/zh active Pending
- 2008-11-04 PL PL10173506.6T patent/PL2295035T3/pl unknown
- 2008-11-04 SI SI200831427T patent/SI2217205T1/sl unknown
- 2008-11-04 HU HUE10173506A patent/HUE028866T2/en unknown
- 2008-11-04 JP JP2010533185A patent/JP5653218B2/ja active Active
- 2008-11-04 PT PT88481544T patent/PT2217205E/pt unknown
- 2008-11-04 KR KR1020157033633A patent/KR101700062B1/ko not_active Ceased
- 2008-11-04 CN CN200880114940A patent/CN101848700A/zh active Pending
- 2008-11-04 SG SG2012081394A patent/SG185951A1/en unknown
- 2008-11-04 KR KR1020107009852A patent/KR101589317B1/ko not_active Ceased
- 2008-11-04 SI SI200832204T patent/SI3067043T1/sl unknown
- 2008-11-04 US US12/741,251 patent/US20100267786A1/en not_active Abandoned
- 2008-11-04 PE PE2013002393A patent/PE20141072A1/es active IP Right Grant
- 2008-11-04 WO PCT/US2008/082324 patent/WO2009061713A1/en not_active Ceased
- 2008-11-04 EP EP22200982.1A patent/EP4186491A1/en active Pending
- 2008-11-04 ES ES08848154.4T patent/ES2536514T3/es active Active
- 2008-11-04 EP EP08848154.4A patent/EP2217205B1/en not_active Revoked
- 2008-11-05 TW TW097142724A patent/TWI484982B/zh active
- 2008-11-05 CL CL2008003298A patent/CL2008003298A1/es unknown
-
2010
- 2010-04-19 IL IL205208A patent/IL205208A/en active IP Right Grant
- 2010-04-30 MA MA32803A patent/MA31797B1/fr unknown
- 2010-04-30 TN TN2010000200A patent/TN2010000200A1/fr unknown
- 2010-05-05 GT GT201000131A patent/GT201000131A/es unknown
- 2010-05-06 EC EC2010010160A patent/ECSP10010160A/es unknown
-
2014
- 2014-08-12 JP JP2014164022A patent/JP2015038069A/ja not_active Withdrawn
-
2015
- 2015-05-14 CY CY20151100426T patent/CY1116280T1/el unknown
-
2016
- 2016-08-02 HR HRP20160988TT patent/HRP20160988T1/hr unknown
- 2016-08-08 CY CY20161100778T patent/CY1117883T1/el unknown
-
2017
- 2017-01-03 IL IL249922A patent/IL249922A0/en unknown
-
2020
- 2020-12-02 US US17/109,716 patent/US20210085631A1/en not_active Abandoned
-
2023
- 2023-05-09 US US18/314,745 patent/US20240115536A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010160A (es) | Composiciones farmaceuticas de accion doble basadas en super-estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidor de endopeptidasa neutra (nep) | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| BR112012006346A2 (pt) | agonista de receptor de acetilcolina, composto, composição farmacêutica, combinação e uso de ativadores de receptor de acetilcolina nicotínico alfa 7 | |
| EA201200968A1 (ru) | Применение транс-кломифена для предотвращения или лечения диабета 2 типа у мужчин | |
| CU23551B7 (es) | Procedimiento para la producción de una composición farmacéutica sólida de administración oral | |
| BRPI0915084B8 (pt) | composto, e, composição farmacêutica | |
| CR9875A (es) | Inhibidores de dipeptidilo peptidasa para tratar diabetes | |
| CL2008001157A1 (es) | Compuestos derivados de quinolina-carboxamida, antagonistas de p2y12; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; composicion de una combinacion de dichos compuestos; y uso del compuesto en el tratamiento de trastornos cardiovasculares, tromboembolismo, infarto agudo al miocardio. | |
| EA201100756A1 (ru) | Способ лечения или профилактики тромбоза с использованием этексилата дабигатрана или его соли с улучшенным профилем безопасности по сравнению со стандартным лечением варфарином | |
| CO6362012A2 (es) | Clohidarto de nalmefeno dihidratado | |
| CO6400186A2 (es) | Tabletas de acetato de ulipristal | |
| MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
| UA110013C2 (uk) | Застосування композиції для лікування шарко-марі-тута і пов'язаних з нею розладів | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| CL2010001123A1 (es) | Uso de piridin-3-ilmetil docosahexanoato para preparar un medicamento util para la prevencion y/o el tratamiento de enfermedades cardiovasculares (divisional solicitud 1848-07). | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
| EA201171497A1 (ru) | Снижение флуктуаций опиоидов в крови | |
| MA32290B1 (fr) | Nouvelle classe de spiro pipéridines pour le traitement de maladies neurodégénératives | |
| MA33563B1 (fr) | 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl | |
| UY32852A (es) | [4-(5-aminometil-fenil)-piperidin-1-il]-1h-indol-3-il]-metanonas disustituidas. | |
| CL2008003780A1 (es) | Compuestos derivados de azetidinas; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento o la prevencion de trastornos psiquiatricos, dependencia o deshabituacion a una sustancia, trastornos cognitivos, enfermedades neurodegenerativas, entre otras. | |
| CO6270299A2 (es) | Composiciones farmaceuticas de accion doble basadas en super estructuras de antagonista/bloqueador del receptor de angiotensina (arb) e inhibidores de endopeptidasa neutra (nep) | |
| CL2009001005A1 (es) | Compuestos derivados de butirato de trimetilamonio, inhibidores de cpt2; proceso de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento o prevencion de enfermedades tales como hiperglucemia, diabetes, hipertension, entre otras patologias. | |
| PA8655401A1 (es) | Nueva composicion farmaceutica que contiene por lo menos un derivado de dolastatina-10 | |
| AR062613A1 (es) | Formulacion de compuestos organicos |